$8.79
2.33% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US75901B1070
Symbol
RGNX

REGENXBIO, Inc. Target price 2024 - Analyst rating & recommendation

REGENXBIO, Inc. Classifications & Recommendation:

Buy
100%

REGENXBIO, Inc. Price Target

Target Price $37.30
Price $8.79
Potential
Number of Estimates 10
10 Analysts have issued a price target REGENXBIO, Inc. 2025 . The average REGENXBIO, Inc. target price is $37.30. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 10 Analysts recommend REGENXBIO, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the REGENXBIO, Inc. stock has an average upside potential 2025 of . Most analysts recommend the REGENXBIO, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 90.24 91.51
19.94% 1.41%
EBITDA Margin -277.94% -229.83%
25.33% 17.31%
Net Margin -329.02% -225.46%
15.69% 31.48%

9 Analysts have issued a sales forecast REGENXBIO, Inc. 2024 . The average REGENXBIO, Inc. sales estimate is

$91.5m
Unlock
. This is
2.78% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$141m 58.07%
Unlock
, the lowest is
$67.9m 23.74%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $90.2m 19.94%
2024
$91.5m 1.41%
Unlock
2025
$297m 224.56%
Unlock
2026
$200m 32.64%
Unlock
2027
$392m 95.73%
Unlock
2028
$520m 32.75%
Unlock

3 Analysts have issued an REGENXBIO, Inc. EBITDA forecast 2024. The average REGENXBIO, Inc. EBITDA estimate is

$-210m
Unlock
. This is
8.44% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-179m 21.93%
Unlock
, the lowest is
$-230m 0.31%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-251m 0.34%
2024
$-210m 16.14%
Unlock
2025
$-42.6m 79.74%
Unlock
2026
$-170m 299.04%
Unlock
2027
$-16.0m 90.62%
Unlock
2028
$47.6m 398.53%
Unlock

EBITDA Margin

2023 -277.94% 25.33%
2024
-229.83% 17.31%
Unlock
2025
-14.35% 93.76%
Unlock
2026
-84.98% 492.20%
Unlock
2027
-4.07% 95.21%
Unlock
2028
9.16% 325.06%
Unlock

3 REGENXBIO, Inc. Analysts have issued a net profit forecast 2024. The average REGENXBIO, Inc. net profit estimate is

$-206m
Unlock
. This is
20.62% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-177m 32.07%
Unlock
, the lowest is
$-230m 11.58%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-297m 7.38%
2024
$-206m 30.51%
Unlock
2025
$26.3m 112.75%
Unlock
2026
$197m 650.11%
Unlock

Net Margin

2023 -329.02% 15.69%
2024
-225.46% 31.48%
Unlock
2025
8.86% 103.93%
Unlock
2026
98.60% 1,012.87%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -6.02 -4.18
7.38% 30.56%
P/E negative
EV/Sales 3.31

3 Analysts have issued a REGENXBIO, Inc. forecast for earnings per share. The average REGENXBIO, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-4.18
Unlock
. This is
20.68% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-3.58 32.07%
Unlock
, the lowest is
$-4.66 11.57%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-6.02 7.38%
2024
$-4.18 30.56%
Unlock
2025
$0.53 112.68%
Unlock
2026
$4.00 654.72%
Unlock

P/E ratio

Current -1.67 26.75%
2024
-2.10 25.75%
Unlock
2025
16.48 884.76%
Unlock
2026
2.20 86.65%
Unlock

Based on analysts' sales estimates for 2024, the REGENXBIO, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.40 18.27%
2024
3.31 2.69%
Unlock
2025
1.02 69.19%
Unlock
2026
1.51 48.46%
Unlock
2027
0.77 48.91%
Unlock
2028
0.58 24.66%
Unlock

P/S ratio

Current 4.88 25.16%
2024
4.75 2.70%
Unlock
2025
1.46 69.19%
Unlock
2026
2.17 48.45%
Unlock
2027
1.11 48.91%
Unlock
2028
0.84 24.66%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today